Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Tuesday, May 16, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, May 16, 2017 /PRNewswire/ --

Next-Generation Sequencing (NGS), Microarray, Circulating

Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques

The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half

of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021, says Visiongain.

While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.

Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 166-page report you will receive 87 charts - all unavailable elsewhere.

The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope • Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.

• 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027: - Advanced PCR Techniques - In Situ Hybridization (ISH) - Circulating Tumour Cells (CTCs) Analysis - Microarray - Next-Generation Sequencing (NGS)

• Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027: - US - EU5 - Japan - China - India - Brazil - Russia - Rest of the World

• Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks: - Roche Diagnostics - Abbott Laboratories - Qiagen - Thermo Fisher Scientific - Agilent Technologies - Hologic - Illumina - Myriad Genetics

• SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.

To request a report overview of this report please email Sara Peerun at or call Tel: +44-(0)-20-7336-6100

Or click on:

The companies mentioned are:

454 Life Sciences Abbott Laboratories AbbVie AbVitro Advanced Cell Diagnostics Advanced Liquid Logic Affymetrix Agendia Agilent Technologies Ambry Amgen Annoroad Applied Biosystems ARCH Venture Partners AstraZeneca Atossa Genetics AvanSci Aviva Biosciences BD Berry Genomics BGI Bina Technologies Biobase Biochain BioFluidica BioMarin Pharmaceutical bioMérieux Bio-Rad BioServe India BlueGnome Bristol-Myers Squibb Bruker Cancer Genetics Cepheid CLC bio CompanionDx Counsyl Crescendo Bioscience CytoTrack Dako DakoCytomation Danaher DiagnoCure DxS Eli Lilly Enzymatics Epic Sciences Epicentre Technologies Epigenomics Exact Sciences Fidelity Management Fluidigm Fluxion GeneDx Genentech Genia Technologies Genomic Health Gen-Probe GnuBio HalioDX Hitachi High-Technologies Hologic Idaho Technology IGEN International Illumina Ingenuity Systems Insilico Medicine Invitae Invitrogen Ipsogen Iquum Iris Molecular Diagnostics Janssen Biotech Janssen Diagnostics LabCorp Life Technologies Luminex Corporation Manostring Technologies Merck Miltenyi Biotec Mylan Myraqa Myriad Genetics NextBio Oncolys BioPharma Ono Pharmaceutical Oxford Nanopore Pacific Biosciences Pathway Genomics Pathway Pharmaceuticals Pensabio PerkinElmer Pfizer Prosigna Qiagen Qiagen Marseille Quest Diagnostics Quidel RainDance Technologies Rarecells Roche Diagnostics Sakura Sanofi ScreenCell Siemens Signature Diagnostics Silicon Biosystems SRI Biosciences Stratos Genomics Sysmex Takeda Thermo Fisher Scientific Twist Bioscience Ventana Medical Systems Verinata Health Vysis

List of Organizations Mentioned in the Report Actionable Genome Consortium Arizona State University Carnegie Mellon University First Oncology Research and Advisory Center Genomics England Institut Curie MGH Cancer Center Massachusetts Institute of Technology National Cancer Center Paris-Descartes University Pennsylvania State University

To see a report overview please email Sara Peerun on

SOURCE Visiongain Ltd

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store